These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23870351)

  • 1. Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012.
    Christie DR
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):499-502. PubMed ID: 23870351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02).
    Christie D; Le T; Watling K; Cornes D; O'Brien P; Hitchins R
    J Med Imaging Radiat Oncol; 2009 Apr; 53(2):203-6. PubMed ID: 19527368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials.
    Nguyen H; Montgomery R; Sundaresan P
    J Med Imaging Radiat Oncol; 2023 Oct; 67(7):703-709. PubMed ID: 37454368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing accrual in cancer clinical trials with a focus on minority enrollment: The William Beaumont Hospital Community Clinical Oncology Program Experience.
    Vicini F; Nancarrow-Tull J; Shah C; Chmielewski G; Fakhouri M; Sitarek SA; Feczko CT; Brzozowski C; Felten DL
    Cancer; 2011 Oct; 117(20):4764-71. PubMed ID: 21455995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group.
    Newman LA; Hurd T; Leitch M; Kuerer HM; Diehl K; Lucci A; Giuliano A; Hunt KK; Putnam W; Wells SA
    J Am Coll Surg; 2004 Oct; 199(4):644-51. PubMed ID: 15454152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain.
    Pollicino CA; Turner SL; Roos DE; O'Brien PC
    Radiother Oncol; 2005 Sep; 76(3):264-9. PubMed ID: 16153729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
    Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
    J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).
    Roos DE; Turner SL; O'Brien PC; Smith JG; Spry NA; Burmeister BH; Hoskin PJ; Ball DL;
    Radiother Oncol; 2005 Apr; 75(1):54-63. PubMed ID: 15878101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.
    Haworth A; Kearvell R; Greer PB; Hooton B; Denham JW; Lamb D; Duchesne G; Murray J; Joseph D
    Radiother Oncol; 2009 Mar; 90(3):299-306. PubMed ID: 19017549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
    Sateren WB; Trimble EL; Abrams J; Brawley O; Breen N; Ford L; McCabe M; Kaplan R; Smith M; Ungerleider R; Christian MC
    J Clin Oncol; 2002 Apr; 20(8):2109-17. PubMed ID: 11956272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to publication of oncology trials and why some trials are never published.
    Chapman PB; Liu NJ; Zhou Q; Iasonos A; Hanley S; Bosl GJ; Spriggs DR
    PLoS One; 2017; 12(9):e0184025. PubMed ID: 28934243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer clinical trials and accrual in the United States.
    Hoos WA; James PM; Rahib L; Talley AW; Fleshman JM; Matrisian LM
    J Clin Oncol; 2013 Sep; 31(27):3432-8. PubMed ID: 23960185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05).
    Roos DE; Davis SR; O'Brien PC; Hoskin PJ; Spry NA; Burmeister BH; Turner SL; Bernshaw DM
    Australas Radiol; 2000 Aug; 44(3):303-7. PubMed ID: 10974724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.
    Hamilton C; Poulsen M; Walker Q; Krawitz H; Hindley A; Spry N; Peters L; Lamb D; Denham J; Steigler A
    Australas Radiol; 1999 May; 43(2):227-32. PubMed ID: 10901907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.
    Dew A; Khan S; Babinski C; Michel N; Heffernan M; Stephan S; Jordan N; Jovanovic B; Carney P; Bergan R
    Clin Trials; 2013 Apr; 10(2):292-9. PubMed ID: 23321266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial accrual among new cancer patients at a community-based cancer center.
    Go RS; Frisby KA; Lee JA; Mathiason MA; Meyer CM; Ostern JL; Walther SM; Schroeder JE; Meyer LA; Umberger KE
    Cancer; 2006 Jan; 106(2):426-33. PubMed ID: 16353206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks.
    McKinney MM; Weiner BJ; Wang V
    Oncol Nurs Forum; 2006 Sep; 33(5):951-9. PubMed ID: 16955123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying barriers to accrual in radiation oncology randomized trials.
    Laba JM; Senan S; Schellenberg D; Harrow S; Mulroy L; Senthi S; Swaminath A; Kopek N; Pantarotto JR; Pan L; Pearce A; Warner A; Louie AV; Palma DA
    Curr Oncol; 2017 Dec; 24(6):e524-e530. PubMed ID: 29270062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The successful contribution by the Trans-Tasman Radiation Oncology Group to intergroup radiation oncology trials (2010-2012) and a proposal for accrual definitions.
    Christie DR; Sharpley CF
    Radiother Oncol; 2014 Jul; 112(1):153-4. PubMed ID: 25023040
    [No Abstract]   [Full Text] [Related]  

  • 20. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP; Lilenbaum RC
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.